Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €88.25 EUR
Change Today 0.00 / 0.00%
Volume 0.0
SANNV On Other Exchanges
Symbol
Exchange
OTC US
BrsaItaliana
Mexico
EN Paris
Frankfurt
Frankfurt
NASDAQ GM
As of 11:00 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-new (SANNV) Snapshot

Open
€87.69
Previous Close
€88.25
Day High
€88.25
Day Low
€87.69
52 Week High
04/13/15 - €95.80
52 Week Low
01/6/15 - €70.35
Market Cap
606.5M
Average Volume 10 Days
21.1K
EPS TTM
--
Shares Outstanding
6.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI-NEW (SANNV)

sanofi-new (SANNV) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi-new (SANNV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi-new (SANNV) Key Developments

Sanofi Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for 2015

Sanofi reported consolidated earnings results for the first quarter ended March 31, 2015. In the first quarter of 2015, the company generated net sales of €8,810 million, an increase of 12.3% on a reported basis (up 2.4% at constant exchange rates). For the first quarter of 2013, net sales were €7,842 million. Business operating income increased 11.8% to €2,398 million in the first quarter against €2,145 million last year. At constant exchange rates, business operating income grew 2.1%. Business net income grew 11.6% to €1,726 million against €1,547 million last year. At constant exchange rates, business net income increased 1.6%. In the first quarter of 2015, business earnings per share were €1.32, up 12.8% on a reported basis and up 2.6% at constant exchange rates. For the first quarter of 2013, business earnings per share were €1.17. Net income attributable to equity holders of Sanofi was €1,023 million against €1,084 million last year. Consolidated earnings per share were €0.78 against €0.82 last year. Operating income was €1,403 million against €1,428 million last year. Income before tax and associates and joint ventures was €1,306 million against €1,387 million last year. In the first quarter of 2015, net cash generated by operating activities was €1,247 million after capital expenditures of €355 million against €279 million in the first quarter of 2014, driven by investment into new biologics capacities and after an increase in working capital by €379 million resulting in particular from inventory seasonality and the build-up of inventory of products. Net debt increased from €7,171 million at December 31, 2014 to €7,571 million at March 31, 2015. Free cash flow was just over €1.2 billion for the period. The company continues to expect 2015 Business EPS to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events. In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately 12%, under the assumption that exchange rates remain stable in the following three quarters at the average rates of March 2015. Now looking at the full year 2015, and excluding dengue vaccine sales, Sanofi Pasteur expects the early sales growth to be in the same range as last year.

Sanofi and Genzyme Announces New Magnetic Resonance Imaging Data from the Lemtrada Clinical Development Program

Sanofi and its subsidiary Genzyme announced that new magnetic resonance imaging data from the Lemtrada clinical development program will be presented at the 67th American Academy of Neurology Annual Meeting. In relapsing remitting multiple sclerosis patients treated with Lemtrada in the Phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study. After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, approximately 70% of Lemtrada patients did not receive additional Lemtrada treatment during the following three years, through month 48. The Phase III trials of Lemtrada were randomized, two-year pivotal studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a in patients with RRMS who had active disease and were either new to treatment or who had an inadequate response to another therapy. Through year four, the adverse event profile of Lemtrada was consistent with that observed during the pivotal studies. The new data being presented at AAN include: The rate of brain atrophy, as measured by brain parenchymal fraction, decreased progressively over four years among Lemtrada patients in CARE-MS I. Among CARE-MS II Lemtrada patients, the rate of brain atrophy decreased progressively over three years and remained low in year four. In both studies, the median yearly brain volume loss was less than -0.20% in years three and four, which was lower than what was observed during the two-year pivotal studies. In CARE-MS I and II, treatment with Lemtrada significantly reduced the risk of developing new lesions compared to interferon beta-1a. In the extension study, most of the Lemtrada-treated patients from CARE-MS I and II were free of new lesions and MRI activity in years three and four. Brain atrophy is a measure of the most destructive pathological processes that occur in MS. 1 It is seen from the earliest stages of disease and may lead to irreversible neurological and cognitive impairment. Given its association with disability, control or prevention of brain atrophy is an important target for MS treatment. In addition, MRI measures including lesion activity are considered useful tools when evaluating the effect of MS therapies, and lesion activity is among several prognostic factors for unfavorable clinical outcomes.

Sanofi, Q1 2015 Earnings Call, Apr 30, 2015

Sanofi, Q1 2015 Earnings Call, Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANNV:FP €88.25 EUR 0.00

SANNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $160.36 USD +2.45
Bayer AG €129.90 EUR +0.89
Gilead Sciences Inc $105.01 USD +4.50
GlaxoSmithKline PLC 1,512 GBp -3.00
Medtronic PLC $75.60 USD +1.15
View Industry Companies
 

Industry Analysis

SANNV

Industry Average

Valuation SANNV Industry Range
Price/Earnings 29.2x
Price/Sales 3.6x
Price/Book -- Not Meaningful
Price/Cash Flow 18.6x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-NEW, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.